BACKGROUND: There is lack of data on the incidence of liver fibrosis (LF) progression in patients with human immunodeficiency virus (HIV) monoinfection and risk factors for LF. METHODS: We performed an observational prospective study in a cohort of HIV-infected patients who had initiated highly active antiretroviral therapy (HAART). FIB-4 and aspartate aminotransferase (AST)-to-platelet ratio index (APRI) were assessed. The concordance between the 2 scores was assessed by weighted kappa coefficient. Kaplan-Meier analysis was used to estimate the incidence of LF. Cox regression analysis was used to assess the predictors of transition. RESULTS: A total of 1112 patients were observed for a mean of 2249 days of follow-up. The concordance between FIB-4 and APRI was moderate (kappa = .573). The incidence of transition to higher FIB-4 classes was 0.064 (95% confidence interval [CI], 0.056-0.072) per person-year of follow-up (PYFU), whereas the incidence of transition to higher APRI classes was 0.099 (95% CI, 0.089-0.110) per PYFU. The incidence of transition to FIB-4 >3.25 was 0.013 per PYFU (95% CI, 0.010-0.017) and 0.018 per PYFU (95% CI, 0.014-0.022) for APRI >1.5. In multivariate analyses, for transition to higher classes, HIV RNA level <500 copies/mL was found to be protective for both scores, and higher CD4+ T cell count was found to be protective for FIB-4. Additional risk factors were age ≥ 40 years, male sex, intravenous drug use as an HIV infection risk factor, higher degree of LF, higher gamma-glutamyl transpeptidase (γGT) at baseline, and use of dideoxynucleoside-analogue drugs (DDX). Consistent results for the main study outcomes were obtained for confirmed LF transition and transition to FIB-4 > 3.25 and APR I> 1.5 as study outcomes. CONCLUSIONS: Overall, our results suggest a possible benefit associated with earlier HAART initiation, provided that the effectiveness of HAART is sustained and treatment with DDX is avoided.
BACKGROUND: There is lack of data on the incidence of liver fibrosis (LF) progression in patients with human immunodeficiency virus (HIV) monoinfection and risk factors for LF. METHODS: We performed an observational prospective study in a cohort of HIV-infectedpatients who had initiated highly active antiretroviral therapy (HAART). FIB-4 and aspartate aminotransferase (AST)-to-platelet ratio index (APRI) were assessed. The concordance between the 2 scores was assessed by weighted kappa coefficient. Kaplan-Meier analysis was used to estimate the incidence of LF. Cox regression analysis was used to assess the predictors of transition. RESULTS: A total of 1112 patients were observed for a mean of 2249 days of follow-up. The concordance between FIB-4 and APRI was moderate (kappa = .573). The incidence of transition to higher FIB-4 classes was 0.064 (95% confidence interval [CI], 0.056-0.072) per person-year of follow-up (PYFU), whereas the incidence of transition to higher APRI classes was 0.099 (95% CI, 0.089-0.110) per PYFU. The incidence of transition to FIB-4 >3.25 was 0.013 per PYFU (95% CI, 0.010-0.017) and 0.018 per PYFU (95% CI, 0.014-0.022) for APRI >1.5. In multivariate analyses, for transition to higher classes, HIV RNA level <500 copies/mL was found to be protective for both scores, and higher CD4+ T cell count was found to be protective for FIB-4. Additional risk factors were age ≥ 40 years, male sex, intravenous drug use as an HIV infection risk factor, higher degree of LF, higher gamma-glutamyl transpeptidase (γGT) at baseline, and use of dideoxynucleoside-analogue drugs (DDX). Consistent results for the main study outcomes were obtained for confirmed LF transition and transition to FIB-4 > 3.25 and APR I> 1.5 as study outcomes. CONCLUSIONS: Overall, our results suggest a possible benefit associated with earlier HAART initiation, provided that the effectiveness of HAART is sustained and treatment with DDX is avoided.
Authors: Joseph K Lim; Janet P Tate; Shawn L Fultz; Joseph L Goulet; Joseph Conigliaro; Kendall J Bryant; Adam J Gordon; Cynthia Gibert; David Rimland; Matthew Bidwell Goetz; Marina B Klein; David A Fiellin; Amy C Justice; Vincent Lo Re Journal: Clin Infect Dis Date: 2014-02-25 Impact factor: 9.079
Authors: Michael J Vinikoor; Edford Sinkala; Aggrey Mweemba; Arianna Zanolini; Lloyd Mulenga; Izukanji Sikazwe; Michael W Fried; Joseph J Eron; Gilles Wandeler; Benjamin H Chi Journal: Liver Int Date: 2015-01-22 Impact factor: 5.828
Authors: E Jennifer Edelman; Stephen A Maisto; Nathan B Hansen; Christopher J Cutter; James Dziura; Lynn E Fiellin; Patrick G O'Connor; Roger Bedimo; Cynthia Gibert; Vincent C Marconi; David Rimland; Maria C Rodriguez-Barradas; Michael S Simberkoff; Amy C Justice; Kendall J Bryant; David A Fiellin Journal: Contemp Clin Trials Date: 2016-11-20 Impact factor: 2.226
Authors: George K Siberry; Rachel A Cohen; D Robert Harris; Maria Leticia Santos Cruz; Ricardo Oliveira; Mario F Peixoto; Maria Celia Cervi; Rohan Hazra; Jorge A Pinto Journal: Pediatr Infect Dis J Date: 2014-02 Impact factor: 2.129
Authors: Bill G Kapogiannis; Erin Leister; George K Siberry; Russell B Van Dyke; Bret Rudy; Patricia Flynn; Paige L Williams Journal: AIDS Date: 2016-03-27 Impact factor: 4.177
Authors: H Nina Kim; Robin Nance; Stephen Van Rompaey; Joseph C Delaney; Heidi M Crane; Edward R Cachay; Elvin Geng; Stephen L Boswell; Benigno Rodriguez; Joseph J Eron; Michael Saag; Richard D Moore; Mari M Kitahata Journal: J Acquir Immune Defic Syndr Date: 2016-08-01 Impact factor: 3.731
Authors: Jennifer C Price; Eric C Seaberg; John P Phair; Mallory D Witt; Susan L Koletar; Chloe L Thio Journal: J Acquir Immune Defic Syndr Date: 2016-07-01 Impact factor: 3.731